A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer.

Jiayu Wang,Binghe Xu,Tao Sun,Quchang Ouyang,Yiqun Han,Qing Li,Pin Zhang,Fei Ma,Yang Luo,Ying Fan,Ruigang Cai,Qiao Li,Bo Lan,Hongnan Mo,Jiani Wang,Yiqun Li

A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer.

2021

Jiayu Wang
Binghe Xu
Tao Sun
Quchang Ouyang
Yiqun Han
Qing Li
Pin Zhang
Fei Ma
Yang Luo
Ying Fan
Ruigang Cai
Qiao Li
Bo Lan
Hongnan Mo
Jiani Wang
Yiqun Li

1074Background: TQB2450 is a humanized monoclonal antibody targeting programmed death-ligand 1 (PD-L1). Anlotinib is an antiangiogenic small molecule, multi-target tyrosine kinase inhibitor that ha...

Keywords:

Cancer research
Phase (matter)
in patient
Monoclonal antibody
Medicine
Triple-negative breast cancer
Tyrosine-kinase inhibitor
Small molecule

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations